Telcare, a Division of BioTelemetry, Inc., Announces Collaboration with Onduo in Diabetes Management Program
November 27 2017 - 4:05PM
(NASDAQ:BEAT) – Telcare, the manufacturer of the world’s first
FDA-cleared cellular-enabled blood glucose monitor, has entered
into a strategic collaboration with Onduo, a joint venture created
by Verily (an Alphabet company) and Sanofi. Under this
partnership, Telcare will serve as the supplier of remote blood
glucose systems and the resulting data for patients enrolled in
Onduo’s groundbreaking diabetes management program.
Onduo will leverage Telcare’s ability to deliver near real-time
blood glucose results to create effective care management programs
targeted primarily to the Type 2 diabetes community. The
Onduo platform integrates service, hardware and software to provide
access to personalized and convenient diabetes care. Onduo’s
team of clinicians and experts combine proven medical practices
with breakthrough technologies to help take the guess work out of
diabetes.
Joseph H. Capper, President and Chief Executive Officer of
BioTelemetry, Inc., commented: “This is an incredibly exciting
partnership for the Telcare team. I believe Onduo’s program
will have a tremendous impact on the lives of the millions of
people living with diabetes. We are pleased to be able to
support Onduo’s innovative approach to diabetes and to be working
with such a dedicated group of individuals.”
About BioTelemetry and Telcare
BioTelemetry, Inc. is the leading wireless medical technology
company focused on the delivery of health information to improve
quality of life and reduce cost of care. The Telcare
division, acquired by BioTelemetry in December 2016, is a leading
digital-health company whose pioneering work includes development
of the first FDA-cleared cellular-enabled glucometer and
cloud-based diabetes data repository system. The Company’s
focus is on providing a comprehensive suite of offerings to support
diabetes management, combining a connected glucometer, cloud-based
analytics and care management tools that enhance care for people
living with diabetes. More information can be found
at www.gobio.com.
About DiabetesDiabetes is a chronic disease
characterized by elevated blood sugar due to inefficient or
deficient insulin production. In 2014, it was estimated that
422 million people globally suffer from the disease.[1]
Diabetes can be classified in two major subsets, type 1 and type 2.
Type 1 diabetes is an autoimmune disease that occurs when the
pancreas stops making insulin and therefore must be regulated via
daily administration of insulin. Type 2 diabetes is a
metabolic disorder in which a person’s body produces insulin, but
is not able to regulate it efficiently. Over time, the
disease can result in serious or life threatening complications,
including damage to the heart, eyes, kidneys and nerves.[2]
It has been estimated that the global economic burden of diabetes
is U.S. $827 billion. [3]
[1] Roglic, G. (2016). Global report on
diabetes. Retrieved August 08, 2016, from
http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1[2] National
Diabetes Statistics Report, 2014. (2014). Retrieved August 8, 2016,
from https://www.cdc.gov/diabetes/pdfs/library/diabetesreportcard2014.pdf[3] NCD
Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes
since 1980: a pooled analysis of 751 population-based studies with
4*4 million participants. Lancet 2016; published online April 7.
http://dx.doi.org/10.1016/S0140-6736(16)00618-8.
FOR
IMMEDIATE RELEASE |
|
|
Contact: |
BioTelemetry, Inc. |
|
Heather C. Getz |
|
Investor Relations |
|
800-908-7103 |
|
investorrelations@biotelinc.com |
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Sep 2023 to Sep 2024